Evaluate the expected performance of MetLife (MET) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
MET may be worth retaining as higher premiums, cost cuts, strong liquidity and a low forward P/E support growth despite its recent underperformance.
MET is embedding pet insurance into shelter adoptions via Petstablished, letting adopters bundle coverage into fees and protect pets from day one.
BRK.B and MET remain resilient amid rate cuts and rising climate risks, but one outpaces the other in terms of ROE and growth.
MetLife, Inc. offers three exchange-traded preferred stocks, providing investors with diversification beyond bank issuers. MET's strong financials, including a AA- S&P rating and net income 18x preferred dividends, support the safety of its preferred stock payouts. Among MET's preferreds, Series A offers the best current yield and floating rate protection in a rising rate environment, though all are callable.
MET beats Q3 EPS estimates and rose 21% year over year as strong Asia results, attributable to higher volumes, and lower expenses offset Latin America tax hit.
MetLife, Inc. ( MET ) Q3 2025 Earnings Call November 6, 2025 9:00 AM EST Company Participants John Hall - Senior VP & Head of Investor Relations Michel Khalaf - CEO, President & Director John McCallion - Executive VP, CFO & Head of Investment Management Lyndon Oliver - Regional President of Asia Ramy Tadros - Regional President of U.S. Business & Head of MetLife Holdings Chuck Davis Eric Sacha Clurfain - Regional President of Latin America Conference Call Participants Ryan Krueger - Keefe, Bruyette, & Woods, Inc., Research Division Thomas Gallagher - Evercore ISI Institutional Equities, Research Division Suneet Kamath - Jefferies LLC, Research Division Taylor Scott - Barclays Bank PLC, Research Division Wesley Carmichael - Autonomous Research US LP Joel Hurwitz - Dowling & Partners Securities, LLC Wilma Jackson Burdis - Raymond James & Associates, Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to the MetLife Third Quarter 202 Earnings Conference Call.
MET is set to post Q3 results on Nov. 5, with estimates hinting at strong revenue and earnings growth despite cost pressures.
Besides Wall Street's top-and-bottom-line estimates for MetLife (MET), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
MetLife enhances its Critical Illness Insurance with a new Cancer Support benefit, offering enhanced care and guidance from Private Health Management experts for patients starting in 2026.
MetLife, Inc. (NYSE:MET ) KBW Insurance Conference 2025 September 3, 2025 10:05 AM EDT Company Participants Michel Khalaf - CEO, President & Director John McCallion - Executive VP, CFO & Head of Investment Management Conference Call Participants Ryan Krueger - Keefe, Bruyette, & Woods, Inc., Research Division Presentation Ryan Krueger Managing Director of Equity Research I'm Ryan Krueger, Life Insurance Analyst at KBW. It's great to have MetLife back with us again this year.
MetLife, Inc. (NYSE:MET ) Q2 2025 Earnings Conference Call August 7, 2025 9:00 AM ET Company Participants Eric Sacha Stephane Clurfain - Regional President of Latin America John Arthur Hall - Senior VP & Head of Investor Relations John Dennis McCallion - Executive VP, CFO & Head of Investment Management Lyndon Oliver - Regional President of Asia Michel Abbas Khalaf - CEO, President & Director Ramy Tadros - Regional President of U.S. Business & Head of MetLife Holdings Conference Call Participants Cave Mohaghegh Montazeri - Deutsche Bank AG, Research Division Elyse Beth Greenspan - Wells Fargo Securities, LLC, Research Division Jamminder Singh Bhullar - JPMorgan Chase & Co, Research Division Joel Robert Hurwitz - Dowling & Partners Securities, LLC Ryan Joel Krueger - Keefe, Bruyette, & Woods, Inc., Research Division Suneet Laxman L. Kamath - Jefferies LLC, Research Division Thomas George Gallagher - Evercore ISI Institutional Equities, Research Division Wesley Collin Carmichael - Autonomous Research US LP Operator Ladies and gentlemen, thank you for standing by.